We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ECX1 market cap is 0. The company's latest EPS is EUR and P/E is N/A.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 1.13M | 843k | 6.2M | 485k | 750k |
| Operating Income | -15.1M | -10.11M | -4.16M | -12.86M | -8.07M |
| Net Income | -17.02M | -11.69M | -2.43M | -12.02M | -4.46M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 13.99M | 6.8M | 24.66M | 15.85M | 12.85M |
| Total Liabilities | 4.36M | 2.93M | 2.54M | 5.68M | 12.85M |
| Total Equity | 9.63M | 3.86M | 22.12M | 10.17M | 0 |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -13.51M | -9.57M | -4.15M | -12.02M | -5.71M |
| Investing | 47k | 3k | 961k | -1.7M | 68k |
| Financing | 7.12M | 2.98M | 21.62M | -359k | -57k |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 4.09M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Epigenomics AG |
| Address |
geneststra��e 5 berlin 10829 |
| Website | https://www.epigenomics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
